- Home
- MFH vs MREO Comparison
MFH vs MREO Comparison
Compare MFH & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- MREO
- Stock Information
- Founded
- MFH 2011
- MREO 2015
- Country
- MFH United States
- MREO United Kingdom
- Employees
- MFH N/A
- MREO N/A
- Industry
- MFH Finance: Consumer Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MFH Finance
- MREO Health Care
- Exchange
- MFH Nasdaq
- MREO Nasdaq
- Market Cap
- MFH 372.5M
- MREO 369.2M
- IPO Year
- MFH N/A
- MREO N/A
- Fundamental
- Price
- MFH $6.08
- MREO $2.41
- Analyst Decision
- MFH
- MREO Strong Buy
- Analyst Count
- MFH 0
- MREO 7
- Target Price
- MFH N/A
- MREO $7.71
- AVG Volume (30 Days)
- MFH 92.0K
- MREO 1.5M
- Earning Date
- MFH 05-16-2025
- MREO 05-19-2025
- Dividend Yield
- MFH N/A
- MREO N/A
- EPS Growth
- MFH N/A
- MREO N/A
- EPS
- MFH N/A
- MREO N/A
- Revenue
- MFH $1,007,430.00
- MREO N/A
- Revenue This Year
- MFH N/A
- MREO N/A
- Revenue Next Year
- MFH N/A
- MREO $56.11
- P/E Ratio
- MFH N/A
- MREO N/A
- Revenue Growth
- MFH 125.92
- MREO N/A
- 52 Week Low
- MFH $1.03
- MREO $1.58
- 52 Week High
- MFH $8.86
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- MFH 47.24
- MREO 50.36
- Support Level
- MFH $5.30
- MREO $2.28
- Resistance Level
- MFH $7.90
- MREO $2.75
- Average True Range (ATR)
- MFH 0.81
- MREO 0.16
- MACD
- MFH -0.08
- MREO -0.00
- Stochastic Oscillator
- MFH 30.00
- MREO 27.66
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).